Shares of Zealand Pharma A/S (NASDAQ:ZEAL) have received an average broker rating score of 1.83 (Buy) from the three brokers that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating on the company.

Brokerages have set a twelve-month consensus price objective of $27.33 for the company and are predicting that the company will post ($0.49) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Zealand Pharma A/S an industry rank of 110 out of 265 based on the ratings given to its competitors.

ZEAL has been the subject of several recent research reports. Guggenheim initiated coverage on Zealand Pharma A/S in a research note on Tuesday, September 5th. They issued a “buy” rating and a $28.00 price target for the company. Needham & Company LLC initiated coverage on Zealand Pharma A/S in a research note on Tuesday, September 5th. They issued a “buy” rating and a $26.00 price target for the company. Morgan Stanley initiated coverage on Zealand Pharma A/S in a research note on Tuesday, September 5th. They issued an “overweight” rating and a $28.00 price target for the company. Goldman Sachs Group, Inc. (The) initiated coverage on Zealand Pharma A/S in a research note on Wednesday, September 27th. They issued a “buy” rating for the company. Finally, Zacks Investment Research raised Zealand Pharma A/S from a “hold” rating to a “buy” rating and set a $17.00 price target for the company in a research note on Wednesday, November 15th.

Shares of Zealand Pharma A/S (NASDAQ:ZEAL) traded up $0.03 during midday trading on Friday, hitting $14.45. The company had a trading volume of 9,200 shares, compared to its average volume of 35,415. Zealand Pharma A/S has a 1-year low of $13.91 and a 1-year high of $20.37.

A number of institutional investors and hedge funds have recently bought and sold shares of ZEAL. Jane Street Group LLC acquired a new stake in Zealand Pharma A/S in the 3rd quarter worth approximately $386,000. Royce & Associates LP acquired a new stake in Zealand Pharma A/S in the 3rd quarter worth approximately $1,152,000. Finally, Susquehanna International Group LLP acquired a new stake in Zealand Pharma A/S in the 3rd quarter worth approximately $3,185,000. Hedge funds and other institutional investors own 5.82% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Analysts Set $27.33 Price Target for Zealand Pharma A/S (ZEAL)” was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.watchlistnews.com/analysts-set-27-33-price-target-for-zealand-pharma-as-zeal/1720331.html.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide-based medicines in Denmark. The company markets Lixisenatide, a once-daily prandial GLP-1 peptide receptor agonist for the treatment of type 2 diabetes under the Adlyxin and Lyxumia names; and Soliqua 100/33/Suliqua, a combination of lixisenatide and insulin glargine, and a GLP-1 receptor agonist for the treatment of type 2 diabetes.

Get a free copy of the Zacks research report on Zealand Pharma A/S (ZEAL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with Analyst Ratings Network's FREE daily email newsletter.